<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475187</url>
  </required_header>
  <id_info>
    <org_study_id>REK 2015/139</org_study_id>
    <nct_id>NCT02475187</nct_id>
  </id_info>
  <brief_title>Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture</brief_title>
  <acronym>thro-fract15</acronym>
  <official_title>Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Measurement of thrombogenic properties by TEG and MEA and observation of thrombotic events
      over 2 years in 220 patients with hip fracture.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with proximal femur fracture have high incidences of thrombotic events. By the two
      &quot;bed-side&quot; methods TEG (Thrombelastography) and MEA (Multiple Electrode Aggregometry), the
      thrombogenic properties of 220 patients with proximal femur fracture will be measured at time
      of hospital admission and 4 times over a period of 6 months postoperatively, and the patients
      will be followed in a total length of 2 years to register thrombotic events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurements of thrombogenic properties by TEG (Maximum Amplitude) and MEA (Units) and thrombotic events in 220 patients with Hip Fracture.</measure>
    <time_frame>24 months</time_frame>
    <description>Thrombogenic properties measured by TEG (different measurements as &quot;MA&quot;) and MEA (measured as &quot;U&quot;) 6 months after operation for hip fracture and clinical thrombotic events over 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurements of thrombogenic properties by TEG (Maximum Amplitude) and MEA (Units) in 220 patients with Hip Fracture.</measure>
    <time_frame>6 months</time_frame>
    <description>Measurements of thrombogenic properties by TEG and MEA in 220 patients patients with Hip Fracture to investigate any correlation between the two Methods and anti-fXa titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of thrombogenic properties by TEG (Maximum amplitude) and MEA (Units)) in the 100 patients with Hip Fracture and thrombotic complications</measure>
    <time_frame>6 months</time_frame>
    <description>Measurements of thrombogenic properties by TEG and MEA (in the first) 100 patients with Hip Fracture and .</description>
  </secondary_outcome>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Thromboembolism</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood tests for Measurments of thrombotic properies. No storage of specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to our hospital for proximal femur fracture and receive orthopedic
        surgery with concomittant thrombosis prophylaxis with LMWH or anticoagulation with
        Warfarin, and are capable to sign/accept informed concent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years who are admitted to our hospital for orthopedic surgery
             of proximal femur fracture.

          -  The study participants must be capable to sign/accept informed concent

        Exclusion Criteria:

          -  Patients with severe dementia or that of other causes not ar capable to give informed
             concent.

          -  Patients with known or suspected cancer, blood diseases or bleeding disorders

          -  Surgery last 6 months

          -  Severe renal- (eGFR (creatinine) &lt;30)

          -  Severe hepatic failure (2x UNL for bilirubin, 3x UNL for ALAT or INR &gt; 1,3 without
             anticoagulation treatment)

          -  Patients that, by drug spesification or -SPC, not are eligible for postoperative
             thrombosis prophylaxis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Øystein Meen, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kongsberg Hospital, Vestre Viken Hospital trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Øystein Meen, Phd</last_name>
    <phone>+47 95807607</phone>
    <email>oystein.meen@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oscar Kristiansen, physician</last_name>
    <phone>+47 47682535</phone>
    <email>cri_osc@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kongsberg Hospital, Vestre Viken Hospital Trust</name>
      <address>
        <city>Kongsberg</city>
        <zip>3611</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Øystein Meen, PhD</last_name>
      <phone>+4795807607</phone>
      <email>oystein.meen@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Oscar Kristiansen, MD</last_name>
      <phone>+4747682535</phone>
      <email>cri_osc@msn.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Dahl OE, Caprini JA, Colwell CW Jr, Frostick SP, Haas S, Hull RD, Laporte S, Stein PD. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost. 2005 May;93(5):860-6.</citation>
    <PMID>15886800</PMID>
  </reference>
  <reference>
    <citation>Cattaneo M. Resistance to anti-platelet agents. Thromb Res. 2011 Feb;127 Suppl 3:S61-3. doi: 10.1016/S0049-3848(11)70017-2.</citation>
    <PMID>21262444</PMID>
  </reference>
  <reference>
    <citation>McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005 Jun;100(6):1576-83.</citation>
    <PMID>15920177</PMID>
  </reference>
  <reference>
    <citation>Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, Prisco D, Abbate R. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol. 2009 Jun;131(6):834-42. doi: 10.1309/AJCPTE3K1SGAPOIZ.</citation>
    <PMID>19461090</PMID>
  </reference>
  <reference>
    <citation>Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101. Epub 2013 Sep 27.</citation>
    <PMID>24076493</PMID>
  </reference>
  <reference>
    <citation>Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schömig A, von Beckerath N, Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost. 2010 Feb;8(2):250-6. doi: 10.1111/j.1538-7836.2009.03709.x. Epub 2009 Nov 28.</citation>
    <PMID>19943882</PMID>
  </reference>
  <reference>
    <citation>Kornblith LZ, Kutcher ME, Redick BJ, Calfee CS, Vilardi RF, Cohen MJ. Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis. J Trauma Acute Care Surg. 2014 Feb;76(2):255-6; discussion 262-3. doi: 10.1097/TA.0000000000000108.</citation>
    <PMID>24458031</PMID>
  </reference>
  <reference>
    <citation>Würtz M, Hvas AM, Christensen KH, Rubak P, Kristensen SD, Grove EL. Rapid evaluation of platelet function using the Multiplate® Analyzer. Platelets. 2014;25(8):628-33. doi: 10.3109/09537104.2013.849804. Epub 2013 Nov 18.</citation>
    <PMID>24246241</PMID>
  </reference>
  <reference>
    <citation>Wilson D, Cooke EA, McNally MA, Wilson HK, Yeates A, Mollan RA. Changes in coagulability as measured by thrombelastography following surgery for proximal femoral fracture. Injury. 2001 Dec;32(10):765-70.</citation>
    <PMID>11754883</PMID>
  </reference>
  <reference>
    <citation>Harr JN, Moore EE, Chin TL, Ghasabyan A, Gonzalez E, Wohlauer MV, Banerjee A, Silliman CC, Sauaia A. Platelets are dominant contributors to hypercoagulability after injury. J Trauma Acute Care Surg. 2013 Mar;74(3):756-62; discussion 762-5. doi: 10.1097/TA.0b013e3182826d7e.</citation>
    <PMID>23425732</PMID>
  </reference>
  <reference>
    <citation>Talsnes O, Hjelmstedt F, Dahl OE, Pripp AH, Reikerås O. Clinical and biochemical prediction of early fatal outcome following hip fracture in the elderly. Int Orthop. 2011 Jun;35(6):903-7. doi: 10.1007/s00264-010-1149-7. Epub 2010 Nov 16.</citation>
    <PMID>21079953</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>February 7, 2016</last_update_submitted>
  <last_update_submitted_qc>February 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TEG</keyword>
  <keyword>MEA</keyword>
  <keyword>Thrombotic events</keyword>
  <keyword>VTE</keyword>
  <keyword>LMWH</keyword>
  <keyword>Hip fractures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

